Biologic Imaging Reagents: Technologies and Global Markets

Report Highlights

The global market for biologic imaging reagents was valued at $9.4 billion in 2011 and is expected to reach $9.9 billion in 2012. Total market value is expected to reach nearly $14.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 7.8%. 

Report Includes

• An overview of the global market for biologic imaging reagents, including those that are commercial or likely to be commercialized within the next five years
• Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
• Coverage of fluorescent probes and dyes; imaging nanomaterials (including quantum dots and other nanoparticles); fluorescent proteins; supermolecules; contrast reagents for MRI, X-ray and ultrasound; and imaging radiopharmaceuticals
• Analysis of each technology to determine its market status and impact on future market segments
• Discussion of imaging reagent producers and the industry structure in specialized segments
• Reviews of industry alliances and acquisitions, and the use of biologic imaging reagents in key diagnostics and R&D tools platforms, including microarrays, lab-on-a-chip devices, DNA sequencing, PCR and cellular analysis
• Comprehensive company profiles of major players in the industry.

Report Scope

The study scope includes the biologic imaging reagents that are commercial or likely to be commercialized within the next five years.  Fluorescent probes and dyes; imaging nanomaterials (including quantum dots and other nanoparticles); fluorescent proteins; contrast reagents for MRI, X-ray and ultrasound; and imaging radiopharmaceuticals are studied.  Both the in-vivo and in-vitro market segments are included.  Each technology is analyzed to determine its market status, impact on future market segments and forecasted growth from 2012 through 2017. Technology status and market driving forces are also discussed.

BCC examines imaging reagent producers and the industry structure in specialized segments of the industry.  We also review industry alliances and acquisitions, and the use of biologic imaging reagents in key diagnostics and research and development (R&D) tools platforms, including microarrays, lab-on-a-chip devices, DNA sequencing, PCR and cellular analysis.  The markets for novel biologic imaging reagent applications, including targeted multifunctional and hybrid therapeutic reagents, are analyzed, and the main companies in these fields are highlighted.

Analyst Credentials

John Bergin has produced successful and highly regarded market research reports in the life science industry for BCC research for more than 10 years. Mr. Bergin has held business development and international sales and marketing positions with Corning Inc., an advanced materials company. He has also held executive management positions with IBC Advanced Technologies, a molecular recognition company specializing in separations. Mr. Bergin's extensive expertise in commercializing new technologies is reflected in his market research reports.

Mr. Bergin received a BS degree in Chemistry and Masters of Business Administration (MBA) degree from Brigham Young University and an MS degree in biotechnology from Johns Hopkins University. John Bergin is a pseudonym of the author.